Dyne Therapeutics, Inc. (DYN)
NASDAQ
17.12
+0.01 (+0.06%)
Closed
Sep 21, 2026
Day's Range
16.7517.59
52 wk Range
11.9227.30
Financial Statements - DYN - Dyne Therapeutics, Inc.
Revenue
0
Net Income
-446.21M▼ 40.6%
EBITDA
-437.97M▼ 28.0%
Free Cash Flow
-423.91M▼ 43.8%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -468.18M | -343.88M | -242.16M | -170.96M | -150.02M | -58.64M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -1.69M | -454K | -1.41M | -54K | -8K | -450K |
| Pre Tax Income | -446.21M | -317.41M | -235.93M | -168.09M | -149.29M | -59.43M |
| Income Tax | - | - | - | - | - | - |
| Net Income | -446.21M | -317.41M | -235.93M | -168.09M | -149.29M | -59.43M |
| EPS Basic | -3.47 | -3.37 | -3.95 | -3.23 | -2.93 | -4.13 |
| EPS Diluted | -3.47 | -3.37 | -3.95 | -3.23 | -2.93 | -4.13 |
| Basic Shares Outstanding | 128.44M | 94.14M | 59.68M | 51.97M | 50.89M | 14.39M |
| Diluted Shares Outstanding | 128.44M | 94.14M | 59.68M | 51.97M | 50.89M | 14.39M |
| Ebit | -440.02M | -343.88M | -242.16M | -170.96M | -150.02M | -59.04M |
| Ebitda | -437.97M | -342.21M | -240.48M | -169.27M | -148.93M | -58.34M |
| Net Income Continuous Operations | -446.21M | -317.41M | -235.93M | -168.09M | -149.29M | -59.43M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
